Abstract:Background: Alcoholic liver disease (ALD) significantly contributes to global liver-related morbidity and mortality. Natural products play a crucial role in the prevention and treatment of ALD. Hydroxysafflor yellow A (HSYA), a unique and primary component of Safflower (Carthamus tinctorius l.), exhibits diverse pharmacological activities. However, the impact and mechanism of HSYA on ALD have not been fully elucidated. Purpose: The purpose of this study was to employ an integrative pharmacology approach to assess the multi-targeted mechanism of HSYA against ALD. Methods: Network pharmacology and molecular docking techniques were used to analyze the potential therapeutic signaling pathways and targets of HSYA against ALD. An ALD model in zebrafish larvae was established. Larvae were pretreated with HSYA and then exposed to ethanol. Liver injury was measured by fluorescence expression analysis in the liver-specific transgenic zebrafish line Tg (fabp10a:DsRed) and liver tissue H&E staining. Liver steatosis was determined by whole-mount oil red O staining and TG level. Additionally, an ethanol-induced hepatocyte injury model was established in vitro to observe hepatocyte damage (cell viability, ALT level), lipid accumulation (oil red O staining, TC and TG), and oxidative stress (ROS, MDA, GPx and SOD) in HepG2 cells treated with or without HSYA. Finally, qRT-PCR combined with network pharmacology and molecular docking was employed to validate the effects of HSYA on targets. Results: HSYA exhibited a significant, dose-dependent improvement in ethanol-induced liver injury in zebrafish larvae and HepG2 cells. Network pharmacology analysis revealed that HSYA may exert pharmacological effects against ALD through 341 potential targets. These targets are involved in various signaling pathways, including lipid metabolism and atherosclerosis, PI3K-Akt signaling pathway, MAPK signaling pathway, and ALD itself. Molecular docking studies displayed that HSYA had a strong binding affinity toward the domains of IL1B, IL6, TNF, PPARA, PPARG, HMGCR and ADH5. qRT-PCR assays demonstrated that HSYA effectively reversed the ethanol-induced aberrant gene expression of SREBF1, FASN, ACACA, CPT1A, PPARA, IL1B, IL6, TNFα, ADH5, and ALDH2 in vivo and in vitro. Conclusion: This study offers a comprehensive investigation into the anti-ALD mechanisms of HSYA using an integrative pharmacology approach. The potential targets of HSYA may be implicated in enhancing ethanol catabolism, reducing lipid accumulation, mitigating oxidative stress, and inhibiting inflammatory response.

Hesperitin attenuates alcoholic steatohepatitis by regulating TLR4/NF-κB signaling in mice

Hesperetin Derivative-14 Alleviates Inflammation by Activating PPAR-γ in Mice with CCl4-induced Acute Liver Injury and LPS-treated RAW264.7 Cells.

Hesperitin Derivative-11 Suppress Hepatic Stellate Cell Activation and Proliferation by Targeting PTEN/AKT Pathway.

Hesperetin Derivative Decreases CCl4‐induced Hepatic Fibrosis by Ptch1‐dependent Mechanisms

Hesperetin Suppresses Inflammatory Responses in Lipopolysaccharide-Induced RAW 264.7 Cells Via the Inhibition of NF-κB and Activation of Nrf2/HO-1 Pathways.

Hesperetin Derivative Attenuates CCl4-induced Hepatic Fibrosis and Inflammation by Gli-1-dependent Mechanisms.

Hesperitin prevents non-alcoholic steatohepatitis by modulating mitochondrial dynamics and mitophagy via the AMPKα-Drp1/PINK1-Parkin signaling pathway

7-O-(2- (Propylamino)-2-oxoethyl) hesperetin attenuates inflammation and protects against alcoholic liver injury by NLRP12

Protective Effects of Hesperetin on Lipopolysaccharide-Induced Acute Lung Injury by Targeting MD2

Hesperetin alleviates aflatoxin B1 induced liver toxicity in mice: Modulating lipid peroxidation and ferritin autophagy

Hesperetin, a SIRT1 activator, inhibits hepatic inflammation via AMPK/CREB pathway

Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation

Protective effects of hesperidin against oxidative stress of tert-butyl hydroperoxide in human hepatocytes

A Comprehensive Review on the Impact of Hesperidin and Its Aglycone Hesperetin on Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Liver Disorders

Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease

Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells

Elucidating hydroxysafflor yellow A's multi-target mechanisms against alcoholic liver disease through integrative pharmacology

Anti-hyperuricemia effect of hesperetin is mediated by inhibiting the activity of xanthine oxidase and promoting excretion of uric acid

Hydroxytyrosol attenuates ethanol-induced liver injury by ameliorating steatosis, oxidative stress and hepatic inflammation by interfering STAT3/iNOS pathway

Hesperetin Attenuated Acetaminophen-Induced Hepatotoxicity by Inhibiting Hepatocyte Necrosis and Apoptosis, Oxidative Stress and Inflammatory Response Via Upregulation of Heme Oxygenase-1 Expression.

Hesperetin Induces Apoptosis of Esophageal Cancer Cells Via Mitochondrial Pathway Mediated by the Increased Intracellular Reactive Oxygen Species